IPGP Earnings

IPGP reported its earnings on 2026-02-12, showcasing a revenue of 274.47M against an estimate of 246.37M, resulting in a 11.41% surprise. The EPS was 0.46, surpassing the expected 0.25 by 84%. The stock experienced a 35.48% price change on the earnings day and a 24.69% change over the next five days, reflecting market reactions to the results.

Following IPGP's earnings announcement on 2026-02-12, the stock price moved by 35.48% on the day of the release. Over the subsequent five days, it saw a 24.69% change. Historically, IPGP's stock price tends to shift by an average of 0.42% in the 10 days leading up to earnings and -1.41% in the 10 days following, providing insight into potential market.

For 2026/Q1, analysts estimate IPGP's annual revenue to reach 244.77M, while the EPS is projected at 0.28. These estimates reflect recent revisions, with revenue estimates unchanged by 0% and EPS estimates unchanged by 0% over the past three months, indicating analyst expectation in the company's performance.

The correlation between IPGP's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock's fundamentals. Over the past three months, revenue estimates for FY2025 were unchanged by 0%, while EPS estimates moved unchanged by 0%. This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, IPGP's stock price typically moves by 0.42% in the 10 days before its earnings and -1.41% in the 10 days after. For the upcoming 2026/Q1 earnings, analysts expect an EPS of 0.28 and revenue of 244.77M.

The earnings call summary highlights strong financial performance, strategic product development, and positive market strategy, with new product launches and expansion in key segments like medical and defense. The Q&A section indicates optimism, with management addressing concerns about margins and growth areas. Despite some uncertainties in management's responses, the overall sentiment is positive, supported by strong interest in new products, growth in key segments, and strategic acquisitions. The market cap suggests moderate stock price sensitivity, leading to a positive outlook for the next two weeks.